Filtered By:
Management: Family Practices

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 250 results found since Jan 2013.

Managing TIA: Early action and essential risk-reduction steps
J Fam Pract. 2022 May;71(4):162-169. doi: 10.12788/jfp.0398.ABSTRACTYour patient with a focal neurologic deficit is rushed to the ED for diagnostic imaging. Which initial and longterm interventions can best reduce their risk of recurrent TIA and stroke?PMID:35730708 | DOI:10.12788/jfp.0398
Source: The Journal of Family Practice - June 22, 2022 Category: Practice Management Authors: Kristen Rundell Shalina Nair Source Type: research

Patients ’ and clinicians’ perceptions of oral anticoagulants in atrial fibrillation: a systematic narrative review and meta-analysis
Atrial fibrillation (AF) increases the risk of developing a stroke by 20%. AF related strokes are associated with greater morbidity. Historically, warfarin was the anticoagulant of choice for stroke prevention...
Source: BMC Family Practice - December 22, 2021 Category: Primary Care Authors: Yeyenta Mina Osasu, Richard Cooper and Caroline Mitchell Tags: Research article Source Type: research

Analysis of CYP2C19 genetic variants with ischaemic events in UK patients prescribed clopidogrel in primary care: a retrospective cohort study
Conclusions A substantial proportion of the UK population carry genetic variants that reduce metabolism of clopidogrel to its active form. In family practice patients on clopidogrel, CYP2C19 LoF variants are associated with substantially higher incidence of ischaemic events. Genotype-guided selection of antiplatelet medications may improve outcomes in patients carrying CYP2C19 genetic variants.
Source: BMJ Open - December 13, 2021 Category: General Medicine Authors: Pilling, L. C., Türkmen, D., Fullalove, H., Atkins, J. L., Delgado, J., Kuo, C.-L., Kuchel, G. A., Ferrucci, L., Bowden, J., Masoli, J. A. H., Melzer, D. Tags: Open access, Cardiovascular medicine Source Type: research

Primary Prevention of CVD with Aspirin: Benefits vs Risks
J Fam Pract. 2021 Jul;70(6S):S41-S46. doi: 10.12788/jfp.0222.ABSTRACTLow-dose aspirin (acetylsalicylic acid [ASA]; 75 to 100 mg/d) is widely used in the prevention of cardiovascular (CV) events based on the results of large-scale studies supporting a benefit. However, questions remain regarding the benefit-risk relationship in certain settings since long-term use of ASA is not devoid of risk. Incontrovertible evidence supports the benefits of ASA treatment, which exceed the risks, in patients who have had a previous CV event (myocardial infarction, stroke, unstable angina, or transient ischemic attack). Nonetheless, the qu...
Source: The Journal of Family Practice - August 25, 2021 Category: Practice Management Authors: Steven M Weisman Stephen Brunton Source Type: research